Posttransplantation Production of Donor HLA-specific Antibodies As a Predictor of Renal Transplant Outcome
Overview
Affiliations
Background: This study aimed to determine whether the production, in renal transplant recipients, of antibodies directed against donor HLA mismatches is predictive of transplant failure.
Methods: The failure study group comprised 112 adult recipients of primary renal transplants who had re-entered the transplant waiting list after failure of the first graft. A control group of 123 recipients with functioning transplants was selected from transplantations performed during the same time period, in which patients had equivalent HLA matching and immunosuppression and a minimum of 5 years of follow-up. Sera taken before transplantation and at 1, 3, and 6 months and annually after transplantation were tested by enzyme-linked immunoabsorbent assay (ELISA) for the presence of HLA class I- and class II-specific antibodies. Antibody specificity was defined by a combination of cytotoxicity, ELISA, and flow cytometry techniques to determine whether the antibodies were directed against donor mismatches.
Results: All recipients were negative for donor HLA-specific antibodies before transplantation. After transplantation, 57 (50.9%) of the 112 patients in the failure group produced donor HLA-specific antibodies compared with 2 (1.6%) of the 123 controls (P<0.0001; odds ratio [OR]=64.98; confidence interval [CI], 14.78-399.51). For 60% of the donor-specific antibody-positive patients, antibodies were detected before transplant failure. In 17 cases, these were class I specific; in 14 cases, class II specific; and in 3 cases, specific for both class I and II.
Conclusions: This study has demonstrated that the production of posttransplantation antibodies directed against donor HLA-A, -B, -Cw, -DR, and -DQ mismatches are all strongly predictive of transplant failure.
Olejkowska N, Gorczyca I, Rekas M, Garley M Cells. 2024; 13(18.
PMID: 39329716 PMC: 11430735. DOI: 10.3390/cells13181532.
Animal Models for Heart Transplantation Focusing on the Pathological Conditions.
Tseng H, Lin Y, Huang C, Shih C, Tsai Y, Liu C Biomedicines. 2023; 11(5).
PMID: 37239085 PMC: 10216327. DOI: 10.3390/biomedicines11051414.
Pereira P, Ribeiro B, Oliveira J, Santos S, Pedroso S, Tafulo S Cureus. 2022; 14(10):e30296.
PMID: 36381702 PMC: 9650953. DOI: 10.7759/cureus.30296.
Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients.
Bath N, Djamali A, Parajuli S, Mandelbrot D, Leverson G, Hidalgo L Kidney360. 2022; 1(12):1407-1418.
PMID: 35372884 PMC: 8815535. DOI: 10.34067/KID.0000122020.
Sharma A, Jorgensen D, Mehta R, Sood P, Puttarajappa C, Wu C Transpl Int. 2022; 35:10094.
PMID: 35368641 PMC: 8967948. DOI: 10.3389/ti.2022.10094.